Cencora, Inc. Form 8-K Filing

On July 31, 2026, Cencora, Inc. entered into an Amended and Restated Credit Agreement to further amend and restate a previous credit agreement. The facility's aggregate commitment was increased from $5.5 billion to $7.0 billion, and the maturity date was extended to July 2031. Changes were also made to covenants, representations, and warranties. Interest rates are based on the company's public debt ratings and range from 69.5 to 110 basis points over Term SOFR, Term CORRA, EURIBO Rate, and RFR, or 0 to 10 basis points over the alternate base rate and Canadian prime rate. The agreement includes affirmative and negative covenants, such as a maximum financial leverage ratio, and events of default. Additionally, on the same date, the company and its subsidiaries entered into an Omnibus Amendment to their receivables securitization facility. This amendment decreased the facility size from $1.5 billion to $1.0 billion but increased the accordion feature to $1.0 billion, allowing for potential increases in commitments subject to bank approval. Technical changes were also made to align financial covenants with the Amended and Restated Credit Agreement. The receivables securitization facility provides liquidity for ongoing business needs, with availability based on accounts receivables originated by AmeriSource Receivables Financial Corporation and AmerisourceBergen Drug Corporation. Cencora, Inc. guarantees the obligations of its subsidiaries under this facility.